IVC Filter Guidelines Published by SIR – Allows Physicians Treating Patients at Risk of a PE to Make Evidence-Based Decisions

September 9, 2020

IVC Filter Guidelines: The Society of Interventional Radiology published new clinical practice guidelines that provide evidence-based recommendations on the use of inferior vena cava filters to treat venous thromboembolism (VTE).

“IVC Filter guidelines allow physicians treating patients at risk of a pulmonary embolism to make evidence-based decisions about the use of IVC filters,” said John A. Kaufman, MD, MS, FSIR, the guidelines’ primary author and chair of the department of interventional radiology at Oregon Health & Science University in Portland. “Throughout the process, the multidisciplinary team followed a gold-standard methodology to ensure we reached the best possible consensus on VTE patient care.”

The guidelines advise against the routine placement of inferior vena cava (IVC) filters in most VTE cases where patients are being successfully treated with anticoagulants. However, if anticoagulation therapies fail or are not indicated for the patient, IVC filters may be considered as a treatment option if clinical risk factors such as bleeding, vascular injury, device migration and increased risk of recurrent deep vein thrombosis (DVT) are considered and deemed low.

When IVC filters are placed, the guidelines recommend a follow-up program to increase retrieval and detect complications. In addition, if patients with retrievable IVC filters are no longer at risk of developing a pulmonary embolism, the guidelines recommend removal unless the risk outweighs the benefits.

“With these multidisciplinary guidelines, the authors have removed any inconsistencies and uncertainties older guidelines may have presented physicians treating patients with VTE,” said SIR President Michael D. Dake, MD, FSIR, senior vice president of the University of Arizona Health Sciences in Tucson. “The authors should be proud of this achievement.”

This is SIR’s first official clinical practice guideline, developed using gold-standard guideline methodology following the Standards for Trustworthy Clinical Practice Guidelines set by the National Academy of Medicine. SIR is committed to continuing developing evidence-based clinical practice guidelines to optimize patient care and improve patient outcomes.

The guidelines were developed in collaboration with and endorsed by the American College of Cardiology, the American Heart Association/American Stroke Association, American College of Surgeons (Committee on Trauma), American College of Chest Physicians (CHEST), Society for Vascular Medicine, Society for Vascular Surgery. The Canadian Association for Interventional Radiology and Cardiovascular and Interventional Radiological Society of Europe have also endorsed the guidelines. The American Society of Hematology has affirmed the value of the statement.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”